Sector News

Rumours resurface over Shire NPS bid

December 18, 2014
Life sciences
The rumour mill is running wild with renewed reports of a possible marriage between Dublin, Ireland-based Shire and US group NPS Pharmaceuticals.
As first reported by Bloomberg, citing sources close to the situation, Shire is considering making an offer for NPS should its flagship hormone replacement therapy Natpara receive a green light from US regulators.
Natpara (recombinant human parathyroid hormone) was filed with the US Food and Drug Administration in October for the treatment of hypoparathyroidism, and a decision is expected towards the end of January.
Though neither party has yet commented on the move, shares in NPS had leapt 20% and Shire’s stock was up nearly 3% in mid-afternoon trading on the Nasdaq on Wednesday.
Interestingly, these are not the first whispers of such a deal; back in June various media reports were suggesting that Shire is planning to make an offer in the region of $4 billion for NPS, though these soon were quashed by the US group.
By Selina McKee
Source: Pharma Times

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]